Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells

Crizotinib is a clinically approved tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EML4-ALK fusion. Crizotinib was originally developed as an inhibitor of MET (HGF receptor), which is involved in the metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Soonbum, Cho, Eun A, Chun, Jung Nyeo, Lee, Da Young, Lee, Sanghoon, Kim, Mi Yeon, Bae, Sang Mun, Jo, Su In, Lee, So Hee, Park, Hyun Ho, Kim, Tae Min, So, Insuk, Kim, Sang-Yeob, Jeon, Ju-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440021/
https://www.ncbi.nlm.nih.gov/pubmed/35999455
http://dx.doi.org/10.1038/s12276-022-00835-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440021/
https://www.ncbi.nlm.nih.gov/pubmed/35999455
http://dx.doi.org/10.1038/s12276-022-00835-8

Ejemplares similares